Interpretation of the Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)
10.3760/cma.j.cn112152-20250819-00408
- VernacularTitle:《中华医学会肺癌临床诊疗指南（2025版）》更新要点解读
- Author:
Bo ZHANG
1
;
Runbo ZHONG
1
;
Hua ZHONG
1
Author Information
1. 上海交通大学医学院附属胸科医院呼吸与危重症医学科，上海 200030
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Guideline;
Interpretation
- From:
Chinese Journal of Oncology
2025;47(10):981-986
- CountryChina
- Language:Chinese
-
Abstract:
The "Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)" was collaboratively completed under the leadership of Professor Han Baohui from the Department of Pulmonary and Critical Care Medicine at Shanghai Chest Hospital and Professor Wang Jie from the Department of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences & Peking Union Medical College. The guideline involved the cooperation of more than 50 lung cancer diagnosis and treatment institutions and over 100 experts across China. Since the completion of the first edition in 2018, the guideline is typically revised annually to promptly incorporate the latest advancements in the field of lung cancer. The most distinctive feature of these guidelines is that they exclusively reference the indications approved by the National Medical Products Administration of China. At the same time, particular emphasis is placed on integrating clinical research data from Chinese scholars based on Chinese patients, thereby enhancing the guidelines' authority, applicability, and drug accessibility. The "Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)" was officially published in September 2025. To better introduce the key points of the guidelines to peers, this interpretation has been prepared.
